Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers

NCT01484600 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: REGN668: Injection Rate 1
DRUG: REGN668: Injection Rate 2

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]